Practical and Theoretical Radiotherapy Physics Course - Application Form

Closing date for registrations: Monday 19th October 2026 

Please complete all questions to ensure successful submission of this form.

Completion of this form does not guarantee you a space on the course. The Course Administrator will contact you after you have submitted this form with further information.

The details you provide on this form will be used for all correspondence and will be used on your certificate.

Loading...
(Please provide your professional/academic email address)

Course Options & Prices

 

1 week

2 weeks

(Tues-Sat)

£800£1350


Which course option would you like to attend?
How do you wish to pay your course fee?

Invoice payments – You will be contacted to submit a Purchase Order to – The Institute of Cancer Research, 123 Old Brompton Rd, London, SW7 3RP.

Online payments – You will be sent a payment link upon receipt of your completed application.  

Please send me accommodation details:
Dietary requirements:
Do you have a food allergy?
Do you require any special assistance?
Please confirm that you are happy for your name, email address and organisation to be passed onto the course lecturers and other delegates attending the Radiotherapy Physics Course by way of an attendee list.
How did you hear about this course?
Please tick box below to confirm:

Latest ICR News

Hand holding magnifying lens pointing at group of different coloured illustrated figures
Cancer trials under the microscope: Study finds barriers to inclusion persist in the UK

08/06/26

A new UK-based study is shedding light on a quiet but consequential problem in cancer research: whether some people have less opportunity than others to participate in clinical trials.
Image of immunofluorescence staining of bladder tumour tissue. Some areas appear lighter green, some dark blue, and others black.
Immunotherapy boost can spare more bladder cancer patients major surgery

02/06/26

An immunotherapy helps bladder cancer patients remain cancer free and enables them to avoid surgery, a phase II trial has found.
Histopathologic image illustrating squamous cell carcinoma.
Immunotherapy injection shrinks tumours in patients with recurrent and/or metastatic head and neck cancer

31/05/26

A targeted cancer treatment given via a simple injection under the skin shrank tumours in more than one third of patients with recurrent and/or metastatic head and neck cancer whose disease has stopped responding to standard treatments, according to research led by scientists at The Institute of Cancer Research, London
Image of pill bottle with pills spilling out
New targeted therapy shrinks advanced gastrointestinal tumours for 61 per cent of patients in an early study

30/05/26

A new, targeted cancer therapy for advanced gastrointestinal stromal tumours (GIST) has shown promising early results, with 61 per cent of patients who received velzatinib as first-line treatment experiencing tumour shrinkage of 30 per cent or over. The results could pave the way for a larger trial to evaluate this therapy as a first-line alternative to imatinib, which has been the standard treatment for more than two decades.